Citations

Clear

3485 citation(s) found for "Sy, Sarah".

Endometriosis biomarkers of the disease: an update
Soto, Diana Encalada , Rassier, Sarah, Green, Isabel C. , Khan, Zaraq , Rassier, Sarah L. Cohen , Burnett, Tatnai L. , Cope, Adela G.

Mayo Clinic

Current Opinion in Obstetrics & Gynecology | July 27, 2022 | Volume: 34 | Issue: 4 | Pages: 210-219

10.1097/gco.0000000000000798 | PMID 35895963 Get It

Purpose of review Endometriosis is a complex benign gynaecologic condition with heterogenous presentations and a large impact on the global healthcare system and on the quality of life for millions of women. Currently, the gold standard for diagnosis involves direct visualization of lesions during surgery confirmed by histopathological diagnosis, resulting in an average delay in its initial diagnosis of 8–10 years. Therefore, the search for noninvasive diagnostic testing options has been subject to a large body of research. Recent findings Multiple potential biomarkers have been explored for noninvasive testing for endometriosis, including glycoproteins, inflammatory cytokines, immunological molecules, angiogenesis markers, hormones, micro RNAs (miRNAs), proteomics, metabolomics, genomics and the microbiome. Summary Although there are challenges to consider, areas for real promise and advancement in the noninvasive diagnosis of endometriosis are currently being explored with real promise in the area of miRNAs, proteomics, metabolomics, genomics and the microbiome.
Utility of Carpal Tunnel Release and Ulnar Decompression in CMT1A and HNPP
Chompoopong, Pitcha , Niu, Zhiyv , Shouman, Kamal , Madigan, Nicolas N. , Sandroni, Paola , Berini, Sarah E. , Brault, Jeffrey S. , Boon, Andrea J. , Laughlin, Ruple S. , Thorland, Erik C., Mandrekar, Jay , Thorland, Erik, Klein, Christopher J , Chompoopong, Pitcha , Niu, Zhiyv , Shouman, Kamal , Shin, Alexander Y. , Klein, Christopher J.

Mayo Clinic

Muscle & Nerve | July 27, 2022 | Volume: 66 | Issue: 4 | Pages: 479-486

10.1002/mus.27687 | PMID 35894586 Get It

Abstract Introduction/Aims Carpal and cubital tunnel syndrome (CTS, CuTS) are common among patients with hereditary neuropathy with liability to pressure‐palsies (HNPP) and Charcot–Marie‐Tooth type 1A (CMT1A) and may impact quality of life. We aimed to evaluate the utility of nerve decompression surgeries in these patients. Methods Medical records were reviewed for patients with PMP22 mutations confirmed in Mayo Clinic laboratories from January 1999 to December 2020, who had CTS and CuTS and underwent surgical decompression. Results CTS occurred in 53.3% of HNPP and 11.5% of CMT1A, while CuTS was present in 43.3% of HNPP and 5.8% of CMT1A patients. CTS decompression occurred in 10‐HNPP and 5‐CMT1A patients, and CuTS decompression with/without transposition was performed in 5‐HNPP and 1‐CMT1A patients. In HNPP, electrodiagnostic studies identified median neuropathy at the wrist in 9/10 patients and ultrasound showed focal enlargements at the carpal and cubital tunnels. In CMT1A, median and ulnar sensory responses were all absent, and the nerves were diffusely enlarged. After CTS surgery, pain, sensory loss, and strength improved in 4/5 CMT1A, and 6/10 HNPP patients. Of clinical, electrophysiologic and ultrasound findings, only activity‐provoked features significantly correlated with CTS surgical benefit in HNPP patients (odds ratio = 117.0:95% confidence interval, 1.94 > 999.99, p = 0.01). One CMT1A and one HNPP patient improved with CuTS surgery while 2 HNPP patients worsened. Discussion CTS symptom improvement post‐surgery can be seen in CMT1A and (less frequent) in HNPP patients. CuTS surgery commonly worsened course in HNPP. Activity‐provoked symptoms in HNPP best informed benefits from CTS surgery.
Targeting VIP and PACAP Receptor Signaling: New Insights into Designing Drugs for the PACAP Subfamily of Receptors
Lu, Jessica Bo Li , Piper, Sarah , Zhao, Peishen , Wootten, Denise , Lu, Jessica , Piper, Sarah J , Miller, Laurence J. , Sexton, Patrick M.

Mayo Clinic

International Journal of Molecular Sciences | July 22, 2022 | Volume: 23 | Issue: 15 | Pages: 8069

10.3390/ijms23158069 | PMID 35897648 Get It

Pituitary Adenylate Cyclase-Activating Peptide (PACAP) and Vasoactive Intestinal Peptide (VIP) are neuropeptides involved in a diverse array of physiological and pathological processes through activating the PACAP subfamily of class B1 G protein-coupled receptors (GPCRs): VIP receptor 1 (VPAC1R), VIP receptor 2 (VPAC2R), and PACAP type I receptor (PAC1R). VIP and PACAP share nearly 70% amino acid sequence identity, while their receptors PAC1R, VPAC1R, and VPAC2R share 60% homology in the transmembrane regions of the receptor. PACAP binds with high affinity to all three receptors, while VIP binds with high affinity to VPAC1R and VPAC2R, and has a thousand-fold lower affinity for PAC1R compared to PACAP. Due to the wide distribution of VIP and PACAP receptors in the body, potential therapeutic applications of drugs targeting these receptors, as well as expected undesired side effects, are numerous. Designing selective therapeutics targeting these receptors remains challenging due to their structural similarities. This review discusses recent discoveries on the molecular mechanisms involved in the selectivity and signaling of the PACAP subfamily of receptors, and future considerations for therapeutic targeting.
Author response: Pathogenic mutations in the chromokinesin KIF22 disrupt anaphase chromosome segregation
Thompson, Alex F. , Blackburn, Patrick R. , Arons, Noah S, Stevens, Sarah N, Babovic‐Vuksanovic, Dusica , Lian, Jane B. , Klee, Eric W. , Stumpff, Jason

Mayo Clinic

No container title available | July 21, 2022 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.7554/elife.78653.sa2 Get It

Comment on: Treatment strategies for clozapine-induced hypotension: A systematic review
Wieruszewski, Patrick M. , Wittwer, Erica D. , Leung, Sarah B., Leung, Jonathan G. , Leung, Jonathan G , Wieruszewski, Patrick M

Mayo Clinic

Therapeutic Advances in Psychopharmacology | July 19, 2022 | Volume: 12 | Issue: No issue available | Pages: No page available

10.1177/20451253221111682 | PMID 35874555 Get It

Community-Based, Cluster-Randomized Pilot Trial of a Cardiovascular Mobile Health Intervention: Preliminary Findings of the FAITH! Trial
Brewer, LaPrincess C. , Jenkins, Sarah M. , Hayes, Sharonne N. , Kumbamu, Ashok , Patten, Christi A. , Hayes, Sharonne N , Brewer, LaPrincess C , Jones, Clarence , Burke, Lora E. , Cooper, Lisa A.

Mayo Clinic

Circulation | July 18, 2022 | Volume: 146 | Issue: 3 | Pages: 175-190

10.1161/circulationaha.122.059046 | PMID 35861762 Get It

Background: African Americans continue to have suboptimal cardiovascular health (CVH) based on the American Heart Association Life’s Simple 7 (LS7), 7 health-promoting behaviors and biological risk factors (eg, physical activity, blood pressure). Innovative, community-level interventions in partnership with trusted institutions such as African American churches are potential means to improve CVH in this population. Methods: Using a community-based participatory research approach, the FAITH! Trial (Fostering African American Improvement in Total Health) rigorously assessed the feasibility and preliminary efficacy of a refined, community-informed, mobile health intervention (FAITH! App) for promoting CVH among African Americans in faith communities using a cluster randomized controlled trial. Participants from 16 churches in Rochester and Minneapolis-St Paul, MN, were randomized to receive the FAITH! App (immediate intervention) or were assigned to a delayed intervention comparator group. The 10-week intervention core features included culturally relevant and LS7-focused education modules, diet/physical activity self-monitoring, and a group sharing board. Data were collected via electronic surveys and health assessments. Primary outcomes were average change in mean LS7 score (continuous measure of CVH ranging from poor to ideal [0–14 points]) from baseline to 6 months post-intervention (using generalized estimating equations) and app engagement/usability (by the Health Information Technology Usability Evaluation Scale; range, 0–5). Results: Of 85 enrolled participants (randomized to immediate [N=41] and delayed [control] intervention [N=44] groups), 76 and 68 completed surveys/health assessments at baseline and 6 months post-intervention, respectively (80% retention rate with assessments at both baseline and 6-month time points); immediate intervention [N=30] and control [N=38] groups). At baseline, the majority of participants (mean age [SD], 54.2 [12.3] years, 71% female) had <4-year college education level (39/66, 59%) and poor CVH (44% in poor category; mean LS7 score [SD], 6.8 [1.9]). The mean LS7 score of the intervention group increased by 1.9 (SD 1.9) points compared with 0.7 (SD 1.7) point in the control group (both P <0.0001) at 6 months. The estimated difference of this increase between the groups was 1.1 (95% CI, 0.6–1.7; P <0.0001). App engagement/usability was overall high (100% connection to app; >75% completed weekly diet/physical activity tracking; Health Information Technology Usability Evaluation Scale, mean [SD], 4.2 [0.7]). Conclusions: On the basis of preliminary findings, the refined FAITH! App appears to be an efficacious mobile health tool to promote ideal CVH among African Americans. Registration: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT03777709.
Sign of the times: Community engagement to refine a cardiovascular mHealth intervention through a virtual focus group series during the COVID-19 Pandemic
Brewer, LaPrincess C. , Cyriac, Jissy , Kumbamu, Ashok , Jenkins, Sarah M. , Hayes, Sharonne N. , Hayes, Sharonne N , Patten, Christi A. , Brewer, LaPrincess C , Burke, Lora E. , Jones, Clarence , Cooper, Lisa A.

Mayo Clinic

DIGITAL HEALTH | July 18, 2022 | Volume: 8 | Issue: No issue available | Pages: 205520762211105

10.1177/20552076221110537 | PMID 35874864 Get It

Background African-Americans are underrepresented in mobile health intervention research studies which can perpetuate health inequities and the digital divide. A community-based, user-centered approach to designing mobile health interventions may increase their sociocultural relevance and effectiveness, especially with increased smartphone use during the coronavirus disease 2019 pandemic. We aimed to refine an existing mobile health intervention via a virtual focus group series. Methods African-American community members (n = 15) from churches in Minneapolis-St. Paul and Rochester, Minnesota were enrolled in a virtual (via videoconferencing), three-session focus group series over five months to refine a cardiovascular health-focused mobile health application (FAITH! [Fostering African-American Improvement in Total Health!] App). Participants accessed the app via their smartphones and received a Fitbit synced to the app. Participants engaged with multimedia cardiovascular health-focused education modules, a sharing board for social networking, and diet/physical activity self-monitoring. Participant feedback on app features prompted iterative revisions to the FAITH! App. Primary outcomes were app usability (assessed via Health Information Technology Usability Evaluation Scale range: 0–5) and user satisfaction. Results Participants (mean age [SD]: 56.9 [12.3] years, 86.7% female) attended a mean 2.8 focus groups (80% attended all sessions). The revised FAITH! App exceeded the goal Health Information Technology Usability Evaluation Scale score threshold of ≥4 (mean: 4.39, range: 3.20–4.95). Participants positively rated updated app content, visual appeal, and use of social incentives to maintain engagement. Increasing user control and refinement of the moderated sharing board were identified as areas for future improvement. Conclusions Community-partnered, virtual focus groups can optimize usability and increase participant satisfaction of mobile health lifestyle interventions that aim to promote cardiovascular health in African-Americans.
Gene Expression Signatures for the Accurate Diagnosis of Peripheral T-Cell Lymphoma Entities in the Routine Clinical Practice
Amador, Catalina , Wright, George W. , Weisenburger, Dennis D. , Greiner, Timothy C. , Lone, Waseem , Heavican, Tayla B., Smith, Lynette M. , Pileri, Stefano , Tabanelli, Valentina , Ott, German , Rosenwald, Andreas , Slack, Graham W. , Kim, Won Seog , Hyeh, Young, Li, Yuping , Dong, Gehong, Ondrejka, Sarah L. , Cook, James R. , Lim, Soon Thye , Ong, Choon Kiat , Chapman, Jennifer R. , Raess, Philipp W. , Blombery, Piers , Morris, Stephan W., Staudt, Louis M. , Chan, Wing C. , Iqbal, Javeed , Greiner, Timothy C , Heavican, Tayla B , Smith, Lynette , Pileri, Stefano , Tabanelli, Valentina , Ott, German , Savage, Kerry J , Kim, Won Seog , Hyeh, Young , Song, Joo Y , Ondrejka, Sarah , Cook, James R , Lim, Soon Thye , Ong, Choon Kiat , Inghirami, Giorgio , Raess, Philipp W , Gould, Clare , Jaffe, Elaine S , Vose, Julie , Chan, Wing C , Iqbal, Javeed , Amador, Catalina , Lone, Waseem G , Wright, George , Bouska, Alyssa , Feldman, Andrew L. , Savage, Kerry J. , Ko, Young Hyeh , Song, Joo Y. , Barrionuevo, Carlos , Inghirami, Giorgio , Bhagavathi, Sharathkumar , Gould, Clare , Jaffe, Elaine S. , Rimsza, Lisa M. , Vose, Julie M.

Mayo Clinic

Journal of Clinical Oncology | July 15, 2022 | Volume: 40 | Issue: 36 | Pages: 4261-4275

10.1200/jco.21.02707 | PMID 35839444 Get It

PURPOSE Peripheral T-cell lymphoma (PTCL) includes heterogeneous clinicopathologic entities with numerous diagnostic and treatment challenges. We previously defined robust transcriptomic signatures that distinguish common PTCL entities and identified two novel biologic and prognostic PTCL-not otherwise specified subtypes (PTCL-TBX21 and PTCL-GATA3). We aimed to consolidate a gene expression–based subclassification using formalin-fixed, paraffin-embedded (FFPE) tissues to improve the accuracy and precision in PTCL diagnosis. MATERIALS AND METHODS We assembled a well-characterized PTCL training cohort (n = 105) with gene expression profiling data to derive a diagnostic signature using fresh-frozen tissue on the HG-U133plus2.0 platform (Affymetrix, Inc, Santa Clara, CA) subsequently validated using matched FFPE tissues in a digital gene expression profiling platform (nCounter, NanoString Technologies, Inc, Seattle, WA). Statistical filtering approaches were applied to refine the transcriptomic signatures and then validated in another PTCL cohort (n = 140) with rigorous pathology review and ancillary assays. RESULTS In the training cohort, the refined transcriptomic classifier in FFPE tissues showed high sensitivity (> 80%), specificity (> 95%), and accuracy (> 94%) for PTCL subclassification compared with the fresh-frozen–derived diagnostic model and showed high reproducibility between three independent laboratories. In the validation cohort, the transcriptional classifier matched the pathology diagnosis rendered by three expert hematopathologists in 85% (n = 119) of the cases, showed borderline association with the molecular signatures in 6% (n = 8), and disagreed in 8% (n = 11). The classifier improved the pathology diagnosis in two cases, validated by clinical findings. Of the 11 cases with disagreements, four had a molecular classification that may provide an improvement over pathology diagnosis on the basis of overall transcriptomic and morphological features. The molecular subclassification provided a comprehensive molecular characterization of PTCL subtypes, including viral etiologic factors and translocation partners. CONCLUSION We developed a novel transcriptomic approach for PTCL subclassification that facilitates translation into clinical practice with higher precision and uniformity than conventional pathology diagnosis.
Chest wall resection for breast cancer: 21st century Mayo clinic experience
Durgan, Diane M., Thomas, Mathew , Pockaj, Barbara A. , McLaughlin, Sarah A. , Casey, William J., Vijayasekaran, Aparna , Wigle, Dennis A. , Cheville, John C. , Tonneson, Jennifer E., Jakub, James W. , De La Cruz Ku, Gabriel, Wigle, Dennis, Tonneson, Jennifer, Hoskin, Tanya L. , Jakub, James W , Thomas, Mathew , Ku, Gabriel De la Cruz

Mayo Clinic

Journal of Surgical Oncology | July 13, 2022 | Volume: 126 | Issue: 6 | Pages: 962-969

10.1002/jso.27014 | PMID 35830290 Get It

AbstractBackgroundWe hypothesized full‐thickness chest wall resection (FTCWR) with advanced surgical techniques and modern systemic therapy is safe, provides local control, and good overall survival.MethodsRetrospective review of FTCWR (including rib or part of sternum) for breast cancer between 2000 and 2020. Primary endpoints included 90‐day morbidities and all‐cause mortality. Secondary endpoints were loco‐regional and distant recurrence, DFS and overall survival (OS).ResultsA total of 35 patients met the criteria. 34 FTCWR were for recurrence and the median time to chest wall recurrence was 6 years. Tumor subtype was triple‐negative in 51% and the remainder HR+ Her2−. 58% were palliative resections. FTCWR included rib(s) in 89% and portion of sternum in 57%; 94% required reconstruction and 80% were R0 resections. There were no 90‐day mortalities. Overall morbidity was 10/35(28%). 17(49%) patients received neoadjuvant systemic therapy for their recurrence and three received neoadjuvant radiation. Adjuvant treatment included chemotherapy (8), endocrine therapy (3), and both (8). Ten patients (28%) received adjuvant radiation. The Median follow‐up was 31 months and there were 6 (17%) loco‐regional and 7 (20%) distant recurrences. OS was 86% and 67% at 1 and 3 years, respectively.ConclusionFTCWR was associated with low morbidity, mortality, recurrence rates, and good OS. Selective FTCWR is safe and has acceptable short‐term survival rates.
Soft Tissue Sarcoma, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology
Mehren, Margaret von , Kane, John M. , Agulnik, Mark , Carr, Janai R. , Connelly, Mary, Ganjoo, Kristen N. , Holder, Ashley M. , Homsi, Jade , Keedy, Vicki L. , Kelly, Ciara M. , Kim, Edward , McCarter, Martin D. , McGarry, Sean V., Mesko, Nathan W. , Meyer, Christian F. , Pappo, Alberto S. , Petersen, Ivy A. , Poppe, Matthew M. , Riedel, Richard F. , Schuetze, Scott M. , Shabason, Jacob E. , Zimel, Melissa N. , Hang, Lisa E., Sundar, Hema, Bergman, Mary Anne, Riedel, Richard F , von Mehren, Margaret , Bui, Marilyn M. , Choy, Edwin , Connelly, Mary, Dry, Sarah , González, Ricardo , Liebner, David A. , Parkes, Amanda , Pollack, Seth M. , Sicklick, Jason Keith , Spraker, Matthew B.

Mayo Clinic

Journal of the National Comprehensive Cancer Network | July 13, 2022 | Volume: 20 | Issue: 7 | Pages: 815-833

10.6004/jnccn.2022.0035 | PMID 35830886 Get It

Soft tissue sarcomas (STS) are rare malignancies of mesenchymal cell origin that display a heterogenous mix of clinical and pathologic characteristics. STS can develop from fat, muscle, nerves, blood vessels, and other connective tissues. The evaluation and treatment of patients with STS requires a multidisciplinary team with demonstrated expertise in the management of these tumors. The complete NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Soft Tissue Sarcoma provide recommendations for the diagnosis, evaluation, and treatment of extremity/superficial trunk/head and neck STS, as well as retroperitoneal/intra-abdominal STS, desmoid tumors, and rhabdomyosarcoma. This portion of the NCCN Guidelines discusses general principles for the diagnosis and treatment of retroperitoneal/intra-abdominal STS, outlines treatment recommendations, and reviews the evidence to support the guidelines recommendations.